<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40923396</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-726X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions</Title><ISOAbbreviation>Catheter Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>Ticagrelor Versus Clopidogrel in Patients With Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ccd.70155</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Current guidelines recommend clopidogrel in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI), yet the comparative benefits are unclear.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The aim of this study was to evaluate the efficacy and safety of ticagrelor versus clopidogrel in patients with CCS undergoing PCI.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched PubMed/MEDLINE, EMBASE, CENTRAL databases from inception to February 15, 2025. We included parallel randomized controlled trials (RCTs) involving adults with CCS undergoing PCI, where the intervention group received ticagrelor as maintenance therapy and the control group received clopidogrel. Primary outcomes included all-cause or cardiovascular mortality, myocardial infarction, quality of life, heart failure, stroke/transient ischemic attack (TIA), revascularization, and adverse events. Study selection and data extraction were conducted independently. We determined the certainty of evidence using the GRADE approach.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We included nine RCTs, with 3370 patients. Compared to clopidogrel, ticagrelor probably results in no important difference in cardiovascular mortality and hospital stay; may not have an important effect on stroke and/or TIA; and may not have an important effect on all-cause mortality, heart failure, and revascularization, but the evidence is very uncertain. Additionally, the evidence is very uncertain about the effect on myocardial infarction. Regarding safety outcomes, ticagrelor probably results in no important difference in major bleeding, minor bleeding, any bleeding, or dyspnea. However, it probably increases the risk of chest pain/tightness (&#x2009;+&#x2009;7.5 per 100; 95% CI: +1.4 to +21.7).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In patients with CCS undergoing PCI, ticagrelor probably has a similar efficacy and safety to clopidogrel in most cardiovascular outcomes. However, it probably increases the risk of chest pain/tightness.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinedo-Avila</LastName><ForeName>Johann Bill</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-4195-5335</Identifier><AffiliationInfo><Affiliation>Unidad de Cuidados Intensivos de Neurocirug&#xed;a del Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valera-Cabrera</LastName><ForeName>Jessica Lucia</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0001-9983-4133</Identifier><AffiliationInfo><Affiliation>Universidad Peruana de Ciencias Aplicadas, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avalos-Rodr&#xed;guez</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universidad San Mart&#xed;n de Porres, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Poma</LastName><ForeName>Sarita M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0002-4916-8416</Identifier><AffiliationInfo><Affiliation>Universidad Nacional Federico Villarreal, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro</LastName><ForeName>Carlos Enrique Mart&#xed;nez</ForeName><Initials>CEM</Initials><Identifier Source="ORCID">0000-0002-5376-4122</Identifier><AffiliationInfo><Affiliation>Universidad Privada Antenor Orrego (UPAO), Trujillo, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ca&#xf1;ote</LastName><ForeName>Renzo G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Oftalmosalud, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chocce</LastName><ForeName>Karina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>EviSalud-Evidencias en Salud, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taype-Rondan</LastName><ForeName>Alvaro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8758-0463</Identifier><AffiliationInfo><Affiliation>EviSalud-Evidencias en Salud, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n para la Generaci&#xf3;n y S&#xed;ntesis de Evidencia en Salud, Vicerrectorado de Investigaci&#xf3;n, Universidad San Ignacio de Loyola, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soriano-Moreno</LastName><ForeName>David R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-3690-0014</Identifier><AffiliationInfo><Affiliation>Escuela de Medicina, Universidad Peruana Uni&#xf3;n, Lima, Peru.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>This study was self-funded by the authors.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Catheter Cardiovasc Interv</MedlineTA><NlmUniqueID>100884139</NlmUniqueID><ISSNLinking>1522-1946</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">angioplasty, balloon, coronary</Keyword><Keyword MajorTopicYN="N">chronic coronary syndrome</Keyword><Keyword MajorTopicYN="N">clopidogrel</Keyword><Keyword MajorTopicYN="N">coronary artery disease</Keyword><Keyword MajorTopicYN="N">platelet aggregation inhibitors</Keyword><Keyword MajorTopicYN="N">ticagrelor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40923396</ArticleId><ArticleId IdType="doi">10.1002/ccd.70155</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>C. Vrints, F. Andreotti, K. C. Koskinas, et al., &#x201c;2024 ESC Guidelines for the Management of Chronic Coronary Syndromes,&#x201d; European Heart Journal 45, no. 36 (2024): 3415&#x2013;3537.</Citation></Reference><Reference><Citation>B. Stark, C. Johnson, and G. A. Roth, &#x201c;Global Prevalence of Coronary Artery Disease: An Update From the Global Burden of Disease Study,&#x201d; supplement, Journal of the American College of Cardiology 83, no. S13 (2024): 2320.</Citation></Reference><Reference><Citation>C. W. Tsao, A. W. Aday, Z. I. Almarzooq, et al., &#x201c;Heart Disease and Stroke Statistics&#x2014;2022 Update: A Report From the American Heart Association,&#x201d; Circulation 145, no. 8 (2022): 153.</Citation></Reference><Reference><Citation>J. S. Lawton, J. E. Tamis&#x2010;Holland, S. Bangalore, et al., &#x201c;2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines,&#x201d; Circulation [Internet] 145, no. 3 (2022): e4&#x2013;e17, https://doi.org/10.1161/CIR.0000000000001038.</Citation></Reference><Reference><Citation>A. Gabaldon&#x2010;Perez, V. Marcos&#x2010;Garces, J. Gavara, et al., &#x201c;Coronary Revascularization and Long&#x2010;Term Survivorship in Chronic Coronary Syndrome,&#x201d; Journal of Clinical Medicine 10, no. 4 (2021): 610.</Citation></Reference><Reference><Citation>S. Q. Khan and P. F. Ludman, &#x201c;Percutaneous Coronary Intervention,&#x201d; Medicine 50, no. 7 (2022): 437&#x2013;444.</Citation></Reference><Reference><Citation>D. A. Angiolillo, M. Galli, J. P. Collet, A. Kastrati, and M. O. O'Donoghue, &#x201c;Antiplatelet Therapy After Percutaneous Coronary Intervention,&#x201d; EuroIntervention 17, no. 17 (2022): e1371&#x2013;e1396.</Citation></Reference><Reference><Citation>J. Silvain, B. Lattuca, F. Beygui, et al., &#x201c;Ticagrelor Versus Clopidogrel in Elective Percutaneous Coronary Intervention (ALPHEUS): A Randomised, Open&#x2010;Label, Phase 3b Trial,&#x201d; Lancet 396, no. 10264 (2020): 1737&#x2013;1744.</Citation></Reference><Reference><Citation>M. Casula, G. Casu, G. Talanas, et al., &#x201c;Efficacy and Safety of P2Y12 Monotherapy vs Standard DAPT in Patients Undergoing Percutaneous Coronary Intervention: Meta&#x2010;Analysis of Randomized Trials,&#x201d; Current Problems in Cardiology 49, no. 8 (2024): 102635.</Citation></Reference><Reference><Citation>M. Valgimigli, F. Gragnano, M. Branca, et al., &#x201c;Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient&#x2010;Level Meta&#x2010;Analysis,&#x201d; JAMA Cardiology 9, no. 5 (2024): 437&#x2013;448.</Citation></Reference><Reference><Citation>C. L. Huang, T. P. Tsao, W. H. Yin, et al., &#x201c;Comprehensive Comparative Efficacy and Safety of Potent P2Y12 Inhibitors in Patients Undergoing Coronary Intervention: A Systematic Review and Meta&#x2010;Analysis,&#x201d; International Journal of Cardiology. Heart &amp; Vasculature 51 (2024): 101359.</Citation></Reference><Reference><Citation>J. P. Higgins, D. G. Altman, P. C. G&#xf8;tzsche, et al., &#x201c;The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials,&#x201d; BMJ (Clinical research ed.) 343 (2011): 5928.</Citation></Reference><Reference><Citation>L. Zeng, R. Brignardello&#x2010;Petersen, M. Hultcrantz, et al., &#x201c;GRADE Guidelines 32: GRADE Offers Guidance on Choosing Targets of GRADE Certainty of Evidence Ratings,&#x201d; Journal of Clinical Epidemiology 137 (2021): 163&#x2013;175.</Citation></Reference><Reference><Citation>N. Santesso, C. Glenton, P. Dahm, et al., &#x201c;GRADE Guidelines 26: Informative Statements to Communicate the Findings of Systematic Reviews of Interventions,&#x201d; Journal of Clinical Epidemiology 119 (2020): 126&#x2013;135.</Citation></Reference><Reference><Citation>B. Lattuca, C. Mazeau, G. Cayla, et al., &#x201c;Ticagrelor vs Clopidogrel for Complex Percutaneous Coronary Intervention in Chronic Coronary Syndrome,&#x201d; JACC: Cardiovascular Interventions 17, no. 3 (2024): 359&#x2013;370.</Citation></Reference><Reference><Citation>S. Manzo&#x2010;Silberman, P. Guedeney, G. Cayla, et al., &#x201c;Ticagrelor vs Clopidogrel in Clopidogrel&#x2010;Naive Patients With Chronic Coronary Syndrome,&#x201d; JACC: Cardiovascular Interventions 17, no. 12 (2024): 1413&#x2013;1421.</Citation></Reference><Reference><Citation>J. J. Rodriguez&#x2010;Arias, J. Gomez&#x2010;Lara, J. Caballero&#x2010;Borrego, et al., &#x201c;Long&#x2010;Term Vascular Function in CTO Recanalization: A Randomized Clinical Trial of Ticagrelor vs. Clopidogrel,&#x201d; Cardiovascular Revascularization Medicine 37 (2022): 61&#x2013;67.</Citation></Reference><Reference><Citation>L. Ortega&#x2010;Paz, W. Bor, F. Franchi, et al., &#x201c;P2Y12 Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention,&#x201d; JACC: Cardiovascular Interventions 17, no. 11 (2024): 1356&#x2013;1370.</Citation></Reference><Reference><Citation>H. G&#xf6;ks&#xfc;l&#xfc;k, Y. Atmaca, M. G. Uluda&#x11f;, et al., &#x201c;Prevention of Minor Myocardial Injury After Elective Percutaneous Coronary Intervention: Comparison of Ticagrelor Versus Clopidogrel,&#x201d; Acta Cardiologica 73, no. 6 (2018): 584&#x2013;590.</Citation></Reference><Reference><Citation>X. Wu, W. You, Z. Wu, et al., &#x201c;Ticagrelor Versus Clopidogrel for Prevention of Subclinical Stent Thrombosis Detected by Optical Coherence Tomography in Patients With Drug&#x2010;Eluting Stent Implantation&#x2014;A Multicenter and Randomized Study,&#x201d; Platelets 32, no. 3 (2021): 404&#x2013;412.</Citation></Reference><Reference><Citation>R. C. Orme, W. A. E. Parker, M. R. Thomas, et al., &#x201c;Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease,&#x201d; Circulation 138, no. 13 (2018): 1290&#x2013;1300.</Citation></Reference><Reference><Citation>Y. C. Chen, F. Y. Lin, Y. W. Lin, et al., &#x201c;DAPT Plus Cilostazol Is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate&#x2010;to&#x2010;Highly Complex Cases: Prospective, Randomized, PRU&#x2010;Based Study in Taiwan,&#x201d; American Journal of Cardiovascular Drugs 19, no. 1 (2019): 75&#x2013;86.</Citation></Reference><Reference><Citation>G. Campo, F. V. Dalla Sega, R. Pavasini, et al., &#x201c;Biological Effects of Ticagrelor Over Clopidogrel in Patients With Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease,&#x201d; Thrombosis and Haemostasis 117, no. 6 (2017): 1208&#x2013;1216.</Citation></Reference><Reference><Citation>M. M. Parizi, R. G. Vafa, A. Ahmadi, et al., &#x201c;Comparison of Ticagrelor and Clopidogrel in Elective Coronary Stenting: A Double Blind Randomized Clinical Trial,&#x201d; Journal of Interventional Cardiology 2023 (2023): 5544440.</Citation></Reference><Reference><Citation>&#x201c;A 30&#x2010;Day, Randomized, Evaluator&#x2010;Blind, Controlled, Multi&#x2010;Centre, Parallel Group, Phase III Study to Evaluate the Effect of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel [Internet],&#x201d; 2025, https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019%E2%80%90002226%E2%80%9079%E2%80%90SE.</Citation></Reference><Reference><Citation>J. Kojuri, &#x201c;A Single&#x2010;Center, Randomized, 6&#x2010;Month, Non&#x2010;Inferiority Study to Compare the Safety and Efficacy of Ticagrelor Monotherapy Versus Dual Antiplatelet Therapy in Chronic Coronary Syndrome Patients Post Percutaneous Coronary Intervention (TICALONE) [Internet],&#x201d; 2024, https://clinicaltrials.gov/study/NCT06509893.</Citation></Reference><Reference><Citation>&#x201c;Pharmacodynamic Effects of Low&#x2010;Dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention Who Are at Risk of Peri&#x2010;PCI Myocardial Infarction Using a Precision Medicine Tool [Internet],&#x201d; University of Florida, 2024, https://clinicaltrials.gov/study/NCT06228456.</Citation></Reference><Reference><Citation>M. G. Kang, J. H. Ahn, K. Kim, et al., &#x201c;Prevalence of Adverse Events During Ticagrelor Versus Clopidogrel Treatment and Its Association With Premature Discontinuation of Dual Antiplatelet Therapy in East Asian Patients With Acute Coronary Syndrome,&#x201d; Frontiers in Cardiovascular Medicine 9 (2022): 1053867.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>